此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effect of Mode of Femoral Nerve Analgesia on Quadriceps Muscle Strength

2014年7月29日 更新者:Hae Wone Chang、Seoul National University Hospital

Effect of Continuous Femoral Analgesia on Quadriceps Muscle Strength-0.2% Ropivacaine Continuous Infusion Versus Patient Controlled Femoral Analgesia

Quadriceps muscle strength is an important determinant of quality of recovery in elderly patients after total knee arthroplasty. We try to compare the quadriceps muscle strength change between 0.2 % ropivacaine continuous fixed femoral infusion and patient controlled femoral analgesia group.

研究概览

地位

未知

条件

详细说明

Continuous femoral nerve analgesia technique is relatively safe, can be easily trained, and reduces significantly intravenous opioid consumption. These favorable features make it standard treatment option for postoperative knee pain. However, direct perineural local anesthetic effect is not only confined into pain fiber, but, the other sensory and motor nerve fibers. Therefore, unwanted motor weakness is accompanied. Quadriceps muscle strength, which is important determinant of physical function after knee arthroplasty, can be influenced in continuous femoral nerve block. Various local anesthetic infusion techniques have been suggested to minimize the change of quadriceps muscle strength. Decreasing local anesthetic concentrations affect not only degree of muscle weakness, but also reduces the quality of pain control. Different anatomic location of catheter tip, considering motor fiber in posterior part of femoral nerve, could not reduce motor weakness. In a study with continuous popliteal-sciatic nerve blocks after hallux valgus repair, repeated bolus administration seems to be more effective method for pain control without concurrent motor impairment. However, another study with continuous femoral nerve block in healthy volunteers, hourly repeated bolus dose of 5 ml of 0.1% ropivacaine failed to spare motor block. Previously, our institution standard technique is fixed continuous infusion of 0.2% ropivacaine and concomitant intravenous patient controlled fentanyl. Because physical therapy of our institution, usually starts with the 2nd day of operation, so, we assume that continuous fixed infusion may result in more drug accumulation near nerve fiber. So, patient controlled mode of femoral analgesia could be better choice for initiation of physical therapy. At the same time, comparison between patient controlled analgesia and continuous infusion is not fully elucidated until recently. Therefore, in this study, we try to compare quadriceps muscle strength change between continuous infusion and patient controlled femoral analgesia in patients undergoing total knee replacement arthroplasty. Secondary outcomes include sensory effect in femoral nerve distribution, pain scores, iv fentanyl consumption, and other adverse effects.

研究类型

介入性

注册 (预期的)

36

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Gyungido
      • Sungnam、Gyungido、大韩民国、463-707
        • 招聘中
        • Seoul National University Bundang Hospital
        • 接触:
        • 首席研究员:
          • Hae Wone Chang, M.D.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 至 80年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • > 21, or < 80 years old- men and women
  • primary, unilateral total knee replacement surgery
  • spinal anesthesia

Exclusion Criteria:

  • general anesthesia
  • secondary knee replacement surgery
  • patient refusal for continuous femoral nerve analgesia technique
  • abnormal coagulation profile, e.g. Prothrombin time international normalized ratio > 1.5, activated partial thrombin time > 50 sec
  • within 5 days after termination oral antiplatelet agent
  • Body mass index>45
  • impaired renal function
  • infection near femoral area
  • previous injury near femoral area
  • neurologic dysfunction in lower limb
  • previous adverse drug reaction for local anesthetics
  • American society of anesthesiologists (ASA) class III, iV or V

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:ropivacaine continuous mode
0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
其他名称:
  • 股神经阻滞
有源比较器:ropivacaine patient controlled mode
0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
其他名称:
  • 股神经阻滞

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change of quadriceps muscle strength
大体时间:Baseline, Postoperative 2nd day
maximum voluntary isometric contraction of quadriceps femoris with hand held manometry
Baseline, Postoperative 2nd day

次要结果测量

结果测量
措施说明
大体时间
sensory changes in femoral nerve distribution
大体时间:postoperative 2 day
tolerance to transcutaneous electrical stimulation
postoperative 2 day
pain scores
大体时间:postoperative 1 day
verbal numeric pain scale (0-100) resting/dynamic
postoperative 1 day
pain scores
大体时间:postoperative 2 day
verbal numeric pain scale (0-100) resting/dynamic
postoperative 2 day
intravenous fentanyl consumption
大体时间:postoperative 2 day
cumulative fentanyl consumption on postoperative 2 day
postoperative 2 day

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Hae Wone Chang, M.D.、Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年2月1日

初级完成 (预期的)

2015年2月1日

研究完成 (预期的)

2015年7月1日

研究注册日期

首次提交

2013年10月28日

首先提交符合 QC 标准的

2013年12月5日

首次发布 (估计)

2013年12月11日

研究记录更新

最后更新发布 (估计)

2014年7月30日

上次提交的符合 QC 标准的更新

2014年7月29日

最后验证

2014年7月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

ropivacaine的临床试验

3
订阅